Immuneering Corp (IMRX)
$1.18
Performance
- $1.15$1.22$1.18
2.54%
Downside
Day's Volatility :5.76%
Upside
3.3%
- $1.00$9.00$1.18
15.25%
Downside
52 Weeks Volatility :88.89%
Upside
86.89%
Returns
| Period | Immuneering Corp | Index (Russel 2000) |
|---|---|---|
3 Months | -13.87% | 0.0% |
6 Months | -82.34% | 0.0% |
1 Year | -85.94% | 0.0% |
3 Years | -95.35% | -22.3% |
Highlights
Market Capitalization | 35.0M |
Book Value | $2.24 |
Earnings Per Share (EPS) | -1.9 |
Wall Street Target Price | 11.07 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -37.42% |
Return On Equity TTM | -61.81% |
Revenue TTM | 455.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -99.8% |
Gross Profit TTM | 158.8K |
EBITDA | -60.1M |
Diluted Eps TTM | -1.9 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.89 |
EPS Estimate Next Year | -1.64 |
EPS Estimate Current Quarter | -0.52 |
EPS Estimate Next Quarter | -0.53 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 838.14%
Technicals Summary
Sell
Neutral
Buy
Immuneering Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Immuneering Corp | 3.51% | -82.34% | -85.94% | -95.35% | -93.29% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Immuneering Corp | NA | NA | NA | -1.89 | -0.62 | -0.37 | NA | 2.24 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Immuneering Corp | Buy | $35.0M | -93.29% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Immuneering Corp
Decreasing Revenue
Revenue is down for the last 2 quarters, 94.41M → -94.41M (in $), with an average decrease of 200.0% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -15.08M → -14.07M (in $), with an average increase of 3.5% per quarter
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 123.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 164.5%
Institutional Holdings
Vanguard Group Inc
3.61%Millennium Management LLC
3.21%T. Rowe Price Associates, Inc.
2.90%Goldman Sachs Group Inc
2.50%Prosight Management, LP
1.85%BlackRock Inc
1.80%
Company Information
Organization | Immuneering Corp |
Employees | 66 |
CEO | Dr. Benjamin J. Zeskind M.B.A., Ph.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$1.18
-0.84%
Keyarch Acquisition Corp
$1.18
-0.84%
Connexa Sports Technologies Inc
$1.18
-0.84%
Us Value Etf
$1.18
-0.84%
First Wave Biopharma Inc
$1.18
-0.84%
Global X Msci Next Emerging
$1.18
-0.84%
Fat Projects Acquisition Corp
$1.18
-0.84%
Capital Link Global Fintech
$1.18
-0.84%
Applied Uv Inc
$1.18
-0.84%